Huatang Ning accelerates volume increase, with the commercial turning point and platform value emerging simultaneously. Hualing Medicine (02552.HK) enters a period of concentrated realization of innovative achievements.

AI Q&A · How can Huatangning’s independent commercialization drive a 2x sales growth?

Recently, leader company in the Hong Kong stock pharma sector, HuaLing Pharma (02552.HK), released its 2025 performance results. For HuaLing Pharma, 2025 is the year in which its strategic value is comprehensively elevated. The company’s core product Huatangning® (dogliflozin tablets) has completed the shift in the Chinese market from co-promotion to full independent commercialization. Sales momentum has accelerated significantly, profitability has improved noticeably, cash conditions have remained robust, and the R&D pipeline has continued to extend outward along the main line of blood glucose homeostasis management.

In terms of specific figures, in 2025, HuaLing Pharma achieved revenue of RMB 493 million, up 93% year over year. Full-year sales volume of Huatangning was approximately 4.01M boxes, up 91% year over year. Gross profit reached RMB 280 million, and gross margin increased to 56.9%. Profit before tax was RMB 1.11B. Cash balance at year-end was approximately RMB 1.09B.

Against the overall environment for China’s innovative drug industry, such performance is very outstanding. In recent years, innovative drug companies have generally faced multiple challenges, including tighter financing, valuation pullbacks, and pressure on commercialization. The market’s focus on Biotech has shifted from “whether there is innovation” to “whether it can deliver.” The performance HuaLing Pharma delivered in 2025 precisely answers the question the capital market cares about most: the product can be sold, revenue growth is fast, the expense structure has improved, the commercialization business is already profitable, and the company has sufficient resources to continue advancing R&D, expanding indications, and building an overseas presence.

1 Independent commercialization fully operational; Huatangning enters a high-quality growth and scaling phase

Starting from January 1, 2025, HuaLing Pharma fully took over the commercialization work of Huatangning in mainland China and quickly established a commercialization system covering 10 sales regions nationwide. The company also assembled a professional team of nearly 200 people for sales, medical affairs, and commercial operations, and launched an AI-enabled digital commercialization platform that significantly improves operating efficiency and sales productivity. This strategy of independent commercialization has produced a track record of high-quality growth.

In 2025, Huatangning sales volume reached 4.01M boxes, representing a major increase from the prior year’s 2.11M boxes. Revenue reached RMB 493 million, approaching a doubling from the prior year’s RMB 256 million. More importantly, this growth was achieved while maintaining stable product pricing, indicating that Huatangning’s scaling was not driven by price cuts to gain volume; instead, it came from genuine market demand release, improved channel penetration, and enhanced terminal promotion efficiency.

Huatangning’s scaling is also closely related to the continued role of coverage under medical insurance. To date, Huatangning has covered more than 500k patients through over 3,000 hospitals, community health centers, pharmacies, and online channels. For chronic disease products such as diabetes, coverage breadth and prescription penetration determine long-term upside. Huatangning has gradually grown from an innovative product in the early stage of launch into a chronic disease management product with a foundation for nationwide promotion. With continued deepening of patient education, physician recognition, and grassroots coverage, this scaling trend is still expected to continue.

Even more noteworthy is that Huatangning’s success proves that China’s homegrown innovative drugs can also run a growth curve by relying on an independent commercialization system. In the past, market concerns about Biotech were largely concentrated on whether “the product can truly be sold.” HuaLing has answered this with data on sales volume, revenue, and patient coverage. The commercialization momentum currently demonstrated by Huatangning lays a solid foundation for the company’s subsequent indication expansion, advancement of combination therapy options, and overseas expansion.

2 Profitability has improved significantly; operating quality is the biggest highlight of this round of results

If high revenue growth indicates that HuaLing Pharma has cracked the market side, then improvements in gross margin, lower expense ratios, and returning the commercialization business to profitability mean the company has begun entering a phase of operating leverage release. In 2025, the company’s gross margin increased to 56.9%, up 8.2 percentage points from the previous year. This reflects the combined results of improved manufacturing efficiency, better plant capacity utilization, and lower unit costs. As sales scale continues to expand, there remains further room for the production-side dilution effect to be released, and Huatangning’s profitability is also expected to keep strengthening.

Regarding selling and distribution expenses, in 2025 the company’s related expenditures were RMB 166 million, up only slightly year over year. However, revenue increased by 93%, driving the selling expense ratio (as a percentage of revenue) to drop sharply from 59.9% to 33.6%. These figures indicate that HuaLing Pharma’s revenue growth rate has already become clearly faster than its expense growth rate. The commercialization system has started to show scale effects, and the marginal output of sales investment is continuously improving.

The company disclosed that in 2025, the commercialization business achieved approximately RMB 115 million in profit, while in the same period of 2024 the business was still loss-making. This change is more worth attention than profit shown in the financial statements alone. It shows that Huatangning is no longer just “sellable”; it is also “more you sell, more you earn,” and the business model itself is becoming mature. For innovative drug companies, the most difficult stage is often crossing from R&D success to commercial success, and HuaLing Pharma has clearly already crossed this threshold.

A stable cash reserve further strengthens confidence in the company’s future development. By the end of 2025, the company’s cash balance was approximately RMB 500k. Ample cash means that HuaLing Pharma has greater strategic initiative when driving expansion of its sales network, promoting in Hong Kong after listing, advancing clinical studies, and developing new products. It not only ensures the continuity of the acceleration in commercialization, but also provides strong support for R&D and internationalization plans in the next stage.

3 Core equity strengthened; global expansion accelerates; growth certainty increases

After 2025, the external environment surrounding Huatangning has also shown clear improvement, providing stronger certainty to support the company’s growth over the next two to three years. First, medical insurance pricing remains stable. Dogliflozin has been recognized as a national innovative drug and an effective treatment for chronic diseases. The national medical insurance catalog prices for 2026 and 2027 will remain unchanged. This means that over the next two full years, the company does not need to bear the price reduction pressure brought by medical insurance renewals. While products continue to scale up, the pricing system can be maintained stable, which has positive significance for revenue quality, profit margins, and the continuity of sales strategies.

Second, the intellectual property protection period is extended further. In February 2026, China’s National Intellectual Property Administration approved the Patent Term Extension (PTE) application for the dogliflozin patent. The core patent protection period was extended by 5 years to April 2034, and an additional five years of market exclusivity rights were added. For innovative drugs, patents and exclusivity periods are key variables that determine the long-term value of assets. A longer protection period means the company has more time to continuously expand product sales scale, broaden into more indications, advance combination therapy plans, and recover prior R&D and commercialization investments with greater ease. Huatangning is currently in a stage where market penetration is rapidly increasing; extending the protection period further opens up the product’s long-term commercial space.

Approval in Hong Kong provides HuaLing Pharma with a new regional growth starting point. On February 27, 2026, dogliflozin obtained listing approval from Hong Kong regulatory authorities. The company plans to formally launch the product in the Hong Kong market in mid-2026, and it had already submitted a new drug registration application to Macau in 2025. The value of the Hong Kong market lies not only in incremental sales revenue, but also in its role as an internationalization bridgehead. Hong Kong has strong international healthcare and regulatory connectivity, and is an important springboard for China’s innovative drugs to move into Southeast Asia and even broader international markets. Starting with Hong Kong, HuaLing Pharma is expected to replicate Huatangning’s commercialization experience and clinical value in regional markets.

Stable medical insurance pricing, extended patents, and Hong Kong approval together construct a complete growth loop for HuaLing Pharma. Stable medical insurance pricing safeguards short- to mid-term revenue quality; extended patents safeguard mid- to long-term asset value; and Hong Kong approval opens up imagination space for regional and international expansion. With these three favorable developments stacking together, it means Huatangning will no longer be merely an innovative drug in a domestic scaling stage. Instead, it will begin to possess platform-like asset characteristics with a longer lifecycle and the ability to expand across more regions.

4 Real-world evidence continues to accumulate; indications and product matrix keep opening long-term upside

The company has not been satisfied with existing indications and current sales scaling. Instead, it has been continuously strengthening clinical evidence for dogliflozin and pushing broader indications and product-matrix expansion around its mechanism characteristics. Among them, real-world studies are the most critical part.

The HMM0701 study has completed enrollment of 380 patients with type 2 diabetes. Interim analysis shows that after 6 months of treatment, HbA1c dropped from 8.1% to 7.3%, and the time in average target range increased to above 70%. The study also indicates that when used in combination with other glucose-lowering drugs, dogliflozin can significantly improve postprandial blood glucose levels and β-cell function. The HMM0601 study has completed enrollment of 2,024 subjects. Preliminary results show that the product has good safety and tolerability among Chinese patients with type 2 diabetes, with no new adverse reactions observed, and it also demonstrates good efficacy in elderly, obese, and hyperglycemic patients. For chronic disease innovative drugs, the significance of these real-world evidence findings is very substantial. They further strengthen confidence in using dogliflozin in real clinical scenarios and provide clinical foundations for subsequent combination therapy and indication expansion.

For the new indication layout, HuaLing Pharma has already formed a relatively clear direction for advancement. MODY-2 is one of the rare disease areas the company is focusing on. Related research shows that dogliflozin has potential to reduce blood glucose to normal levels, improve glucose sensitivity, and enhance second-phase pancreatic insulin secretion in such patients. The company expects to submit the relevant IND application in 2026. Diabetes prevention is another direction with tremendous upside for imagination. The company has launched the SENSITIZE3 study in Hong Kong, conducting a double-blind, placebo-controlled trial in patients with impaired glucose tolerance and early diabetes. In the future, it is expected to help move the product from the treatment setting to the prevention setting. Mild cognitive impairment and neurodegenerative diseases have also been listed as important research priorities. HuaLing Pharma is exploring the relationship between glucose homeostasis and neurological function, aiming to open new boundaries of disease management. At the same time, the company will also include frailty in its potential layout, further connecting glucose homeostasis management with the theme of healthy aging.

The enrichment of the product matrix is also being accelerated. The development of the fixed-dose combination product of dogliflozin with metformin continues to progress. The company has submitted an IND application to the NMPA, and the GMP commercial manufacturing process has already been completed, preparing for the key study for the 2027 NDA. The value of FDC lies in improving patient adherence and enhancing convenience for prescriptions, and it is expected to further strengthen product competitiveness in long-term medication scenarios. Significant progress has also been made in developing the second-generation GKA. This product targets the once-daily treatment setting for obese diabetes patients. It has started multiple-dose dose-escalation studies in the United States, and top-line data are expected to be released in mid-2026. If the second-generation GKA advances smoothly, it will provide HuaLing Pharma with a new round of growth engine targeting the global metabolic disease market.

The potential of combination therapy further amplifies the platform value of dogliflozin. The company is advancing explorations into combination use with GLP-1 receptor agonists, SGLT-2 inhibitors, and other drugs. Recent study results show that after 12 weeks of combination therapy of dogliflozin and semaglutide, improvements in glycemic control, weight-related metrics, and β-cell function are all better than semaglutide monotherapy. One of the core trends in the global metabolic disease treatment field today is multi-mechanism combination therapy. If dogliflozin can secure a stable position in this trend, its commercial value and strategic position will be significantly enhanced. It is not only an innovative drug sold individually; it also has the opportunity to become a key component in future metabolic disease combination therapy regimens.

5 Conclusion

Overall, the core signal conveyed by HuaLing Pharma’s full-year 2025 performance is very clear: the company has completed the key transition from being driven by innovative R&D to being driven by commercial realization. Huatangning’s market position continues to be strengthened, profitability has started to be released, the external policy and intellectual property environment has improved significantly, the product evidence system and R&D pipeline are expanding in parallel, and the path to future growth is becoming increasingly clear.

2025 is a turning-point year for HuaLing Pharma, and 2026 is expected to become the key year for amplifying its growth outcomes. As the Chinese market continues to scale up, the Hong Kong market officially takes root, real-world data continues to accumulate, the second-generation GKA and new indications continue to be advanced, HuaLing Pharma is expected to grow from an early mover in China’s diabetes innovative drug field into a more representative benchmark company in China’s metabolic disease innovative treatment sector.